As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: April 1, 2012
by News Stand 24/7
“Clearance is impaired in Alzheimer’s disease,” says study author Randall Bateman. “We compared a group of 12 patients with early Alzheimer’s disease to 12 age-matched and cognitively normal subjects. Both groups produced amyloid-beta (a-beta) at the same average rate, but there’s an average drop of about 30 percent in the clearance rates of the group with Alzheimer’s.”
Scientists calculate that it would take 10 years for this decrease in clearance to cause a build-up of a-beta equal to those seen in the brains of Alzheimer’s patients.
The results have important implications for both diagnosis and treatment, according to the authors. Scientists are now interested in learning how a-beta, a byproduct of normal metabolism, is moved out of the brain for breakdown and disposal. As these details come in, they will be essential for physicians working to diagnose the disease before symptoms develop.
A-beta was recognized long ago as a key component of the brain plaques found during autopsies of Alzheimer’s patients. One of the ways the brain clears away the a-beta normally produced by brain cell activity is by moving it to the spinal fluid for disposal. Studies have suggested that a drop in spinal fluid levels of a-beta may be a presymptomatic indicator of Alzheimer’s disease, possibly because a-beta is getting stuck in the brain and starting to accumulate there.
Recent failures of therapies designed to clear a-beta from the brain have led some neurologists to speculate that a-beta may not be causatively linked to Alzheimer’s. According to Bateman, though, the new data show that Alzheimer’s is associated with disruption of the brain’s ability to handle a-beta normally.
“These findings support the idea that impaired a-beta clearance is fundamentally linked to Alzheimer’s disease,” Bateman says.
For the new study, scientists used stable isotope-linked kinetics (SILK), a process Bateman and his colleagues developed, to assess a-beta clearance and production rates.
During SILK, researchers give test subjects an intravenous drip of the amino acid leucine that has been very slightly altered to label it.
Over the course of hours, cells in the brain pick up the labeled leucine and incorporate it into the new copies they make of a-beta and other proteins. Scientists take periodic samples of the subjects’ cerebrospinal fluid through a lumbar catheter, purify the a-beta from the samples and determine how much of the a-beta includes labeled leucine.
Tracking the rise of a-beta with labeled leucine over time gives scientists the subject’s a-beta production rate. When the percentage of a-beta containing labeled leucine plateaus, researchers stop introducing labeled leucine. Periodic sampling of the patients’ CSF continues, allowing scientists to get a measurement of how quickly the nervous system clears out the labeled a-beta.
Average clearance rate for a-beta differed significantly between the 12 normal subjects and the 12 with early Alzheimer’s, but some normal subjects had lower clearance rates close to or slightly within the range seen in Alzheimer’s patients.
“Cognitive tests show no signs of dementia in these participants now, but we’ll be interested to see if a lower clearance rate is a predictive marker for future diagnosis of Alzheimer’s disease,” Bateman says.
It is a devastating omission that may have undercut years of work by brilliant researchers from around the world. Millions of dollars and countless hours have been spent investigating dementia. But in the view of...
A stroll through the Dutch community of De Hogeweyk is a journey to what could be the future of dementia care. Located within the small town of Weesp, just outside of Amsterdam, De Hogeweyk is...
Intimate-partner violence (IPV) is a pattern of physical and/or sexual violence inflicted by an intimate or ex-intimate partner. Global estimates published by the World Health Organization indicate that about 1 in 3 women have experienced...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.